Stoke Therapeutics (STOK) Receivables - Net (2024 - 2026)

Stoke Therapeutics has reported Receivables - Net for 3 years, with the latest figure at $4.5 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables - Net changed N/A year-over-year to $4.5 million; the trailing twelve-month figure through Mar 2026 stood at $4.5 million (changed N/A YoY), and the FY2025 full-year result was $5.9 million, up 255.88% from the prior year.
• Receivables - Net for Q1 2026 stood at $4.5 million, down from $5.9 million in the prior quarter.
• The five-year high for Receivables - Net was $9.2 million in Q3 2025, with the low at $1.7 million in Q4 2024.
• Average Receivables - Net over 3 years is $5.3 million, with a median of $5.2 million recorded in 2025.
• Peak annual rise in Receivables - Net reached 255.88% in 2025, while the deepest fall reached 255.88% in 2025.
• Tracing STOK's Receivables - Net over 3 years: stood at $1.7 million in 2024, then surged by 255.88% to $5.9 million in 2025, then dropped by 25.02% to $4.5 million in 2026.
• The last three Receivables - Net figures came in at $4.5 million (Q1 2026), $5.9 million (Q4 2025), and $9.2 million (Q3 2025), per Business Quant data.

Peer Comparison